ATAIBECKLEY INC (ATAI)
Health Care · Biotechnology · NASDAQ
Atai Beckley is a clinical-stage biotech firm developing novel treatments for central nervous system disorders.
What ATAIBECKLEY INC does
Atai Beckley is a clinical-stage biotechnology company focused on the development of therapeutics for central nervous system (CNS) disorders. The company operates as a research-intensive enterprise, advancing a pipeline of product candidates through preclinical and clinical development stages.
Themes: biotechnology, CNS disorders, clinical-stage therapeutics, drug development
Fundamentals
- Price$7.35 last close before the listing ended, 2026-09-11
- Market cap$2.7B as of 2026-08-07 (share count; price 2026-09-11)
- 1-year return+59.8% 2025-09-11 close $4.60 → 2026-09-11 close $7.35
- P/En/a negative earnings
- Net margin-16142.0% FY2025, SEC XBRL
- ROE-297.5% FY2025, SEC XBRL
- ROICn/a No figure: its pre-tax income was zero or negative, so there is no tax rate to apply.
- Debt / equity0.13 borrowings, leases excluded / equity — 10-Q/10-K balance sheet 2026-06-30
- Revenue growth (YoY)+1227.6% FY2025, SEC XBRL
- Beta1.39 as of 2026-09-03
- Last reported earnings2026-05-12 SEC EDGAR Form 8-K (Item 2.02)
No longer listed. This listing has ended. The figures below are historical: the last on record, from 2026-09-11, not a current quote.
How ATAI compares in its sector
- net profit marginbottom 10% 430 covered Health Care peers, as of 2026-09-03
- operating marginbottom 10% 417 covered Health Care peers, as of 2026-09-03
- return on equitybottom 10% 510 covered Health Care peers, as of 2026-09-03
- free cash flow (absolute dollars, latest fiscal year)bottom 25% 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
ATAI is not currently in any published Top 10 list. Its scores are below.
Top 10 score
Not scored for the top 10 list: the listing has ended.
Scores as of 20 Oct 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 4.
Quarterly results
| Quarter | Revenue | Operating income | Net income | Diluted EPS | Operating cash flow | Capex |
|---|---|---|---|---|---|---|
| Q2 FY2026 2026-06-30 | $2M | -$44M | -$33M | -$0.09 | -$35M† | $0† |
| Q1 FY2026 2026-03-31 | $954000 | -$31M | -$30M | -$0.08 | -$21M | $0 |
| Q2 FY2025 2025-06-30 | $719000 | -$25M | -$28M | -$0.14 | -$14M† | $127000† |
| Q1 FY2025 2025-03-31 | $2M | -$20M | -$26M | -$0.15 | -$18M | $268000 |
† Not filed as a discrete quarter: derived from the company's own year-to-date figures (for example the fourth quarter as the fiscal year minus the first nine months). A derived per-share figure is approximate, because the share count moves within the year.
Balance sheet at 2026-06-30
- Cash and equivalents$169M
- Total debt$23M borrowings only; leases excluded
- Net debt-$146M total debt − cash − short-term investments
From the company's own SEC 10-Q and 10-K filings (XBRL), re-read every week. Figures in US dollars as filed; informational only — not financial advice.
Analyst consensus
- Consensus ratingHold (2.85 mean, 1=Strong Buy…5=Strong Sell) — 6 analysts
- Mean price target$8.12 range $7.45 – $9.25; median $7.75
Analyst estimates, as of 2026-10-05. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for ATAI
- Consensus EPS estimate-$0.1196 next reporting period, as of 2026-10-05
- Estimate change, 30 days-$0.00791 from -$0.1117, on 2026-09-01, 34-day window
- Readings revised upward17% of 6 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Clinical-stage company with a history of significant losses and no guarantee of future profitability.","Regulatory and commercial risks associated with developing drugs that target the CNS, including the use of controlled substances.","Substantial uncertainty and risks related to a pending merger agreement, including potential failure to close or diversion of management resources."]
Insider activity (SEC Form 4)
No open-market insider purchases or sales recorded in the last 90 days, of which we have read Form 4 filings through 2026-10-16. The 5 days since 2026-10-16 have not been checked yet.
- Last 180 days · read to 2026-10-160 buys · 3 sells ($938031) — 3 selling insiders
Most recent open-market transaction: 2026-07-07. Based on Form 4 filings read through 2026-10-16; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about ATAI's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
4 institutional 13F filers reported holding ATAI as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 4
- Reported shares held 38,905,145
- Reported value $205,030,115
reported quarterly holdings change (2026-03-31 → 2026-06-30): 1 new, 3 increased, 0 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about ATAI's institutional holders → See what each manager we track holds →
Short interest (FINRA)
ATAI had 19,201,689 shares of reported short interest as of the 2026-08-31 FINRA settlement date (delayed, bi-monthly; not real-time).
ATAI had 5.18% of its shares outstanding sold short as of the 2026-08-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 2.77 days to cover at the same settlement.
- Reported short interest (shares) 19,201,689
- Short interest (% of shares outstanding) 5.18%
- Prior settlement (shares) 16,855,502
- Reported change 13.92%
- Days to cover (reported) 2.77
Reported to FINRA as of the 2026-08-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Compass Pathways
- MindMed (MNMD)
- Cybin (CYBN)
- Sage Therapeutics
- Axsome Therapeutics (AXSM)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare ATAI vs…
ATAIBECKLEY INC is found in…
Frequently asked questions
What does ATAIBECKLEY INC (ATAI) do?
Atai Beckley is a clinical-stage biotechnology company focused on the development of therapeutics for central nervous system (CNS) disorders. The company operates as a research-intensive enterprise, advancing a pipeline of product candidates through preclinical and clinical development stages.
What sector is ATAIBECKLEY INC (ATAI) in?
ATAIBECKLEY INC (ATAI) is classified in the Health Care sector. Its industry is Biotechnology. It trades on NASDAQ.
Who are ATAIBECKLEY INC's (ATAI) competitors?
Notable peers of ATAIBECKLEY INC (ATAI) include Compass Pathways, MindMed, Cybin, Sage Therapeutics and Axsome Therapeutics. This peer set is informational only — not financial advice.
Where does stocks-llm's data on ATAI come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. This listing has ended, so these are the last figures on record rather than current ones — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are the last daily closes recorded before this listing ended.
Last updated 2026-09-11.
Informational only — NOT financial advice. All figures are the last on record before this listing ended, from SEC EDGAR & market data, shown with their as-of date.